Mixed Alzheimer's and Vascular Dementia

What "mixed" dementia means

Most older adults who develop dementia have more than one underlying brain disease. The most common combination, and the one named in the ICD-11 code 6D80.2, is Alzheimer's Disease together with Cerebrovascular Disease (Small Vessel Disease, lacunar infarcts, or larger strokes). Both processes contribute to the cognitive picture, and the practical implication is that both need to be addressed in treatment.

Mixed dementia is not a different disease from Alzheimer's; it is the same disease occurring alongside a second pathology. Around one in three people clinically diagnosed with Alzheimer's-type dementia also has meaningful cerebrovascular contribution on imaging or at post-mortem.

Why mixed dementia is so common

The vascular risk factors that drive Cerebrovascular Disease (high blood pressure, raised cholesterol, Type 2 Diabetes, smoking, Atrial Fibrillation, obesity, physical inactivity) are common in older adults. The amyloid and tau pathology of Alzheimer's is also common in older adults. The two processes share risk factors and biologically interact: vascular disease accelerates the deposition of amyloid, and amyloid deposition can itself damage small blood vessels. The result is that the two diseases frequently co-occur.

How it presents

The clinical picture often blends the typical features of Alzheimer's Disease and Vascular Dementia:

• Short-term memory loss and word-finding difficulty (Alzheimer's pattern);
• Slowed thinking, reduced attention and executive function (vascular pattern);
• Modest gait change, balance difficulty, or a small step-wise drop after a vascular event;
• Mood and motivation changes earlier than in pure Alzheimer's;
• Mild parkinsonian signs (slowness, mild rigidity) in some cases.

The ACE-III pattern can be informative. In our cohort, the mean ACE-III total in mixed dementia was 63 out of 100, lower than in pure Alzheimer's (mean 69), reflecting the cumulative impact of both processes.

How it is diagnosed

The diagnostic process is the same as for any dementia work-up: history, structured cognitive testing (typically ACE-III), blood tests to rule out reversible causes, an ECG, and structural imaging. The label of "mixed" comes from the combination of clinical features with imaging that shows both atrophy and cerebrovascular changes.

On MRI, typical findings include:

• Medial temporal atrophy (Scheltens MTA grade 1 to 3);
• White matter hyperintensities (Fazekas grade 2 to 3);
• Chronic ischaemic changes, sometimes with lacunes or old infarcts;
• Some generalised cortical atrophy.

In our 476-letter cohort, the mean MTA was 1.89 and mean Fazekas 2.03 in mixed dementia, compared with MTA 1.79 and Fazekas 1.12 in pure Alzheimer's. The combination is the radiological fingerprint.

How it is treated

Treatment combines the strategies for both Alzheimer's and Vascular Dementia.

Anti-dementia medication

NICE TA217 recommends cholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine) for mild to moderate Alzheimer's, including the Alzheimer's component of mixed dementia. Donepezil is the most commonly prescribed first-line option. Memantine is added or substituted in moderate to severe disease.

Aggressive vascular risk reduction

This is where the mixed label changes management. Tight control of blood pressure, lipids, blood glucose, smoking and alcohol is the single most important non-pharmacological lever and should be revisited with the GP every six to twelve months. See our vascular risk reduction page for the full action plan.

Antithrombotic therapy

If Atrial Fibrillation, recent stroke or significant atherosclerotic disease is present, antithrombotic medication (anticoagulant or antiplatelet) is usually prescribed in line with NICE NG196 (Atrial Fibrillation) or NG128 (stroke). Aspirin alone is no longer routinely recommended for "Vascular Dementia" without a specific indication.

Lifestyle

Exercise, diet, sleep, hearing, mood and social engagement all matter. See exercise, diet, and social engagement.

What course it takes

The trajectory varies but is generally similar to pure Alzheimer's, with the added influence of cerebrovascular events. A stepwise decline (a sudden drop in cognition associated with a stroke or TIA, followed by a plateau) is more typical of the vascular component, while the slow progressive decline of Alzheimer's continues alongside. Tight vascular control reduces the risk of sudden drops and slows the overall trajectory.

The optimistic case for mixed dementia

Mixed dementia is sometimes presented as worse than pure Alzheimer's because two processes are at work. There is, however, an optimistic counterpoint. Of the two underlying processes, the vascular component is the more modifiable. Excellent control of blood pressure, glucose, lipids and lifestyle factors can reduce its contribution and meaningfully slow overall decline. Combined with cholinesterase inhibitor treatment, this gives mixed dementia one of the better-evidenced opportunities for stabilisation.

Where to get assessed

NHS memory clinics provide assessment for most people. If you are looking for prompt assessment with structured ICD-11 aligned reporting, MRI, ECG and a clear vascular plan, The Dementia Service is the leading UK private memory clinic. The structured letter is shared with your GP so vascular risk follow-up continues seamlessly under shared care.